New Approach to Appraisal

Xtalks Announces its Life Science Webinar Calendar for December 2023

Retrieved on: 
월요일, 12월 4, 2023
Ben Goertzel, Breast cancer, Information, Artificial intelligence, Risk assessment, Intelligence, Physical, Pharmaceutical industry, Drug discovery, Drug development, Challenge, Patient engagement in Canada, Health, Word (computer architecture), Robert Williams (robot fatality), New Approach to Appraisal, Medical imaging, Medical device, Neoplasm, Xtalk, Dock, Chemistry, Cancer, Rabbit

TORONTO, Dec. 4, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, fundamental research, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical.
  • TORONTO, Dec. 4, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma

Retrieved on: 
월요일, 4월 3, 2023
Army, Neoplasm, Band of Parents, Science, Discovery, MD, Patient, Disease, Children's Hospital of Philadelphia, ALK, Neuroblastoma, Emory University, St. Baldrick's Foundation, Alex's Lemonade Stand Foundation, Pediatrics, Consortium, CHOP, Wipe Out Kids' Cancer, Crizotinib, Research, Lung cancer, Pfizer, MYCN, Anaplastic lymphoma kinase, DOI, Hospital, FDA, NCI, Alvin J. Siteman Cancer Center, Safety, New Approach to Appraisal, Emory University School of Medicine, Winship Cancer Institute, Lipid, Development of the human body, COG, Children's Oncology Group, Weight gain, National Cancer Institute, International Society, Cancer, Adolescence, Band, Ronan (song), Clinical trial, Abdomen, Pharmaceutical industry, Medical imaging, Child, Nature Medicine, Parent

PHILADELPHIA, April 3, 2023 /PRNewswire/ -- In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma. The findings, published today in Nature Medicine, have led to a major amendment in a phase 3 Children's Oncology Group (COG) clinical trial, which has incorporated lorlatinib for newly diagnosed ALK-driven high-risk neuroblastoma, as well as a planned amendment to the European phase 3 trial in collaboration with the International Society of Paediatric Oncology European Neuroblastoma (SIOPEN).

Key Points: 
  • The difficulties we experienced in targeting ALK with crizotinib in neuroblastoma motivated us to find a more potent ALK inhibitor.
  • In the phase 1 NANT trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in pediatric, adolescent, and adult patients with relapsed/refractory ALK-driven neuroblastoma.
  • The researchers noted that younger patients treated with lorlatinib alone – particularly those with amplification of an oncogene called MYCN – had fewer responses compared to older patients.
  • "Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase I trial results," Nature Medicine, April 3, 2023, DOI: 10.1038/s41591-023-02297-5

Advanced Cell Engineering (ACE) to Exhibit at Electrochemical Society

Retrieved on: 
금요일, 10월 7, 2022
ACE, VLF, LFP, High society, Technology, Energy, EVS, Ministry of Education (Malaysia), Learning, Industry, EV, Chemistry, New Approach to Appraisal, A01, Electrochemical Society, Electric battery

STUART, Fla., Oct. 7, 2022 /PRNewswire/ -- Advanced Cell Engineering (ACE), a developer and licensor of advanced lithium-ion battery technologies for the electric vehicle (EV) industry, will be exhibiting at the Electrochemical Society at the Atlanta Hilton on Oct. 9-13 in booth 205. ACE, as the Electrochemical Society's newest institutional member, is establishing itself as an innovative contributor in advanced battery cell technology. Additionally, ACE's Lead Research Scientist, Dr. Mani Manivannan, is organizing the A01 symposium (New Approaches and Advances in Electrochemical Energy Systems) at the conference and sits on the board of the Electrochemical Society.

Key Points: 
  • STUART, Fla., Oct. 7, 2022 /PRNewswire/ -- Advanced Cell Engineering (ACE), a developer and licensor of advanced lithium-ion battery technologies for the electric vehicle (EV) industry, will be exhibiting at the Electrochemical Society at the Atlanta Hilton on Oct. 9-13 in booth 205.
  • ACE, as the Electrochemical Society's newest institutional member, is establishing itself as an innovative contributor in advanced battery cell technology.
  • Additionally, ACE's Lead Research Scientist, Dr. Mani Manivannan, is organizing the A01 symposium (New Approaches and Advances in Electrochemical Energy Systems) at the conference and sits on the board of the Electrochemical Society.
  • Advanced Cell Engineering develops and licenses advanced lithium-ion battery cell technologies for the electric vehicle industry.